PROVIREX Genome Editing Therapies GmbH is a biopharmaceutical company focused on the development and commercialization of innovative gene therapies. The company uses state-of-the-art genome editing technologies to develop novel therapies for serious and previously incurable diseases. The focus is on the treatment of genetically determined diseases, especially those with a high medical need.
PROVIREX aims to improve the lives of patients through the development of groundbreaking therapies. The company pursues a patient-centered approach and places great emphasis on scientific excellence, innovation and the highest quality standards. The company's values include integrity, transparency and a strong commitment to ethical research and development.
Although the sources provided do not contain specific information on PROVIREX's sustainability goals and initiatives, it is common for biopharmaceutical companies today to also address environmental and social aspects. It is therefore likely that PROVIREX is also committed to sustainable practices in research, development and production in order to minimize environmental impact and make a positive contribution to society. This could include, for example, reducing waste, optimizing energy consumption and promoting diversity and inclusion in the workplace.
